MYD88 and lymphoma: The myeloid differentiation primary response 88 (MYD88) protein is an important adaptor molecule in Toll-like receptors signaling that prompts the activation of NF-kB and the production of both inflammatory cytokines and type I interferons.[8] Previous studies have indicated that MYD88 mutations in lymphoma are gain-of-function mutations, the most common variant of which is the L265P (c.794T>C) mutation in the evolutionarily conserved hydrophobic core of the Toll/IL1 receptor domain of MYD88.